Aminopyrimidines useful as inhibitors of protein kinases

• US 8,518,953 B2
• Filed: 06/02/2010
• Issued: 08/27/2013
• Est. Priority Date: 03/09/2007
• Status: Active Grant

• Current Assignee: Vertex Pharmaceuticals Incorporated
• Original Assignee: Vertex Pharmaceuticals Incorporated
• Inventors: Pierce, Albert, Come, Jon, Court, John, Henkel, Gregory, Liu, Michael, Neuberger, Timothy, Gao, Huai
• Primary Examiner(s): RAO, DEEPAK R
• Application Number:
  US12/792,050
• Publication Number:
  US 20110020377A1
• Time in Patent Office: 1,182 Days
• Field of Search: 544/328, 514/256
• US Class Current: 514/256
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 21/02 Muscle relaxants, e.g. for tetanus or cramps
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.

Claims

1. A compound having the following structure:

2. A composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

3. A method of treating or lessening the severity of a disease or condition selected from stroke and diabetic neuropathy comprising the step of administering to a patient a compound according to claim 1.

4. The method of claim 3, wherein the compound is administered after ischemia has occurred.

5. The method of claim 3, wherein the compound is used for post-stroke recovery.

6. The method of claim 3, comprising the additional step of administering to said patient an additional therapeutic agent selected from an agent for treating stroke or an agent for treating diabetic neuropathy.